Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan and docetaxel, work in different
ways to stop tumor cells from dividing so they stop growing or die. Combining more than one
chemotherapy drug may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving irinotecan together with docetaxel
works in treating patients with refractory metastatic breast cancer.